Percheron Therapeutics ATHJF Stock
Percheron Therapeutics Price Chart
Percheron Therapeutics ATHJF Financial and Trading Overview
| Percheron Therapeutics stock price | 0.06 USD |
| Previous Close | 0.05 USD |
| Open | 0.05 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.05 - 0.05 USD |
| 52 Week Range | 0.04 - 0.09 USD |
| Volume | 10K USD |
| Avg. Volume | 2.15K USD |
| Market Cap | 35.25M USD |
| Beta (5Y Monthly) | 0.643678 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ATHJF Valuation Measures
| Enterprise Value | 17.01M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.530725 |
| Price/Book (mrq) | 2.0833333 |
| Enterprise Value/Revenue | 8.461 |
| Enterprise Value/EBITDA | -2.097 |
Trading Information
Percheron Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.643678 |
| 52-Week Change | -28.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.09 USD |
| 52 Week Low | 0.04 USD |
| 50-Day Moving Average | 0.05 USD |
| 200-Day Moving Average | 0.06 USD |
ATHJF Share Statistics
| Avg. Volume (3 month) | 2.15K USD |
| Avg. Daily Volume (10-Days) | 1K USD |
| Shares Outstanding | 669.32M |
| Float | 532.59M |
| Short Ratio | N/A |
| % Held by Insiders | 20.28% |
| % Held by Institutions | 4.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -404.024% |
| Gross Margin | 97.94% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.51% |
| Return on Equity (ttm) | -40.55% |
Income Statement
| Revenue (ttm) | 2.01M USD |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | 89.50% |
| Gross Profit (ttm) | 1.71M USD |
| EBITDA | -8115440 USD |
| Net Income Avi to Common (ttm) | -8102384 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.62M USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 185.37K USD |
| Total Debt/Equity (mrq) | 1.16 USD |
| Current Ratio (mrq) | 8.998 |
| Book Value Per Share (mrq) | 0.024 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6765062 USD |
| Levered Free Cash Flow (ttm) | -3775655 USD |
Profile of Percheron Therapeutics
| Country | United States |
| State | VIC |
| City | Toorak |
| Address | 14 Wallace Avenue |
| ZIP | 3142 |
| Phone | 61 3 9827 8999 |
| Website | https://www.antisense.com.au |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Q&A For Percheron Therapeutics Stock
What is a current ATHJF stock price?
Percheron Therapeutics ATHJF stock price today per share is 0.06 USD.
How to purchase Percheron Therapeutics stock?
You can buy ATHJF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Percheron Therapeutics?
The stock symbol or ticker of Percheron Therapeutics is ATHJF.
Which industry does the Percheron Therapeutics company belong to?
The Percheron Therapeutics industry is Drug Manufacturers-Specialty & Generic.
How many shares does Percheron Therapeutics have in circulation?
The max supply of Percheron Therapeutics shares is 1.64B.
What is Percheron Therapeutics Price to Earnings Ratio (PE Ratio)?
Percheron Therapeutics PE Ratio is 0.00000000 now.
What was Percheron Therapeutics earnings per share over the trailing 12 months (TTM)?
Percheron Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Percheron Therapeutics company belong to?
The Percheron Therapeutics sector is Healthcare.